Clinical Trials Logo

Clinical Trial Summary

Cannabidiol (CBD) is another cannabis plant derivative for which, like THC, there has been extensive research. Unlike THC however, CBD is non-intoxicating and non-psychedelic. CBD has antipsychotic effects. Logically, if CBD opposes THC effects, it may be a potential antipsychotic treatment. The purpose of this pilot research is to show target engagement of the hippocampus with the study drug (CBD versus placebo) in patients who have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder with psychosis compared to healthy controls.


Clinical Trial Description

The investigators conjecture that CBD may act both to modify THC effects and to reduce psychosis symptoms (at least in part) through downstream ECS-related mechanisms, both of which actions converge on the hippocampus, a region rich in CB1 receptors. As such, observing hippocampus activity levels using fMRI can be an effective means of measuring CBD target engagement within this pilot study context. The purpose of this pilot research is to show target engagement of the hippocampus with the study drug cannabidiol (CBD) versus placebo, in BSNIP Biotype 3 compared to Biotypes 1 and 2 and to healthy control subjects, during performance of an fMRI paired associated memory task. Here, investigators will use B-SNIP-based observations in already-characterized B-SNIP subjects, to predict in which individuals CBD engages a theoretically-based brain target. In turn (in future planned studies) such engagement may predict CBD treatment responders. At present, CBD is still an experimental drug for psychosis treatment (although now FDA-approved for treatment of specific types of childhood seizures), but one with a rather benign side-effect profile that could easily be added to ongoing antipsychotic treatment. The purpose of the study is to study response to a single, acute dose of CBD compared to placebo, under double-blind conditions in a small-scale pilot study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04778644
Study type Interventional
Source Hartford Hospital
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date December 15, 2021
Completion date December 15, 2025

See also
  Status Clinical Trial Phase
Completed NCT04976738 - A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain Phase 1/Phase 2
Not yet recruiting NCT04729244 - The Study of Hemp Oil CBD for Evaluation of Efficacy and Safety in Treatment of Pain, Anxiety and Insomnia Management Phase 1
Recruiting NCT05490511 - Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus Phase 1
Withdrawn NCT04412837 - The Use of Cannabinoid Patch for Knee Osteoarthritis Phase 2
Completed NCT05121506 - A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults Phase 1
Completed NCT04360044 - Efficacy of Inhaled Cannabis for Acute Migraine Treatment Phase 2
Recruiting NCT04611347 - Topical CBD in Joint Arthritis Phase 2
Enrolling by invitation NCT04680130 - Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
Recruiting NCT04398719 - CBD-Microglia PET Study Early Phase 1
Completed NCT04423341 - Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Phase 2/Phase 3
Active, not recruiting NCT04997954 - EMERALD TRIAL Open Label Extension Study Phase 4
Recruiting NCT04030442 - Cannabidiol, Morphine, Pain Phase 1
Completed NCT04851392 - Do Adolescents and Adults Differ in Their Acute Response to Cannabis? N/A
Completed NCT04777643 - Sex Differences in Neural Response to Cannabidiol Early Phase 1
Recruiting NCT05956834 - A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
Recruiting NCT05562635 - CBD (Cannabidiol) Intraoral Application and TMD (Temporomandibular Disorders) Phase 2/Phase 3
Active, not recruiting NCT04831294 - Effects of Cannabidiol (CBD) on the Brain N/A
Recruiting NCT04686539 - Synthetic CBD as a Therapy for COVID-19 Phase 1
Active, not recruiting NCT04482244 - RCT of CBD for Anxiety in Advanced Breast Cancer Phase 2
Recruiting NCT04775030 - Methodology for Developing an Occlusal Appliance With CBD Active Carrier Phase 2/Phase 3